News
RFL
1.220
-1.61%
-0.020
Weekly Report: what happened at RFL last week (0323-0327)?
Weekly Report · 4d ago
Weekly Report: what happened at RFL last week (0316-0320)?
Weekly Report · 03/23 09:53
Rafael Holdings GAAP EPS of -$0.13
Seeking Alpha · 03/16 21:04
Rafael Holdings Q2 EPS $(0.13) Up From $(0.19) YoY, Sales $211.000K Up From $77.000K YoY
Benzinga · 03/16 20:03
*Rafael Holdings: We Are on Track to Complete 96-Week Phase 3 Trial, Report Preliminary Top Line Results in 3Q >RFL
Dow Jones · 03/16 20:02
Press Release: Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
Dow Jones · 03/16 20:01
Press Release: Rafael Holdings Reports Second -2-
Dow Jones · 03/16 20:01
Weekly Report: what happened at RFL last week (0309-0313)?
Weekly Report · 03/16 09:53
Weekly Report: what happened at RFL last week (0302-0306)?
Weekly Report · 03/09 09:54
Evaluating Alzheimer's Disease Treatments
Seeking Alpha · 03/04 10:33
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 03/03 12:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 03/02 17:05
Weekly Report: what happened at RFL last week (0223-0227)?
Weekly Report · 03/02 09:53
Weekly Report: what happened at RFL last week (0216-0220)?
Weekly Report · 02/23 09:53
Weekly Report: what happened at RFL last week (0209-0213)?
Weekly Report · 02/16 09:52
Weekly Report: what happened at RFL last week (0202-0206)?
Weekly Report · 02/09 09:54
Weekly Report: what happened at RFL last week (0126-0130)?
Weekly Report · 02/02 09:54
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 01/30 21:05
Weekly Report: what happened at RFL last week (0119-0123)?
Weekly Report · 01/26 09:54
Weekly Report: what happened at RFL last week (0112-0116)?
Weekly Report · 01/19 09:58
More
Webull provides a variety of real-time RFL stock news. You can receive the latest news about Rafael Holdings through multiple platforms. This information may help you make smarter investment decisions.
About RFL
Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. The Company's segments include Healthcare, Infusion Technology and Real Estate. The Company’s lead candidate is Trappsol Cyclo, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder. The Healthcare segment comprises equity interests in LipoMedix Pharmaceuticals Ltd., Barer Institute Inc., Cornerstone Pharmaceuticals, Inc., Cyclo, and Rafael Medical Devices, LLC. The Real Estate segment consists of the Company’s real estate holdings, which comprise a portion of one commercial building in Israel. The Infusion Technology segment comprises equity interests in Day Three Labs, Inc. LipoMedix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company.